New insights into p53 regulation and gene therapy for cancer

Biochemical Pharmacology

Volumn 60, Issue 8, 2000, Pages 1153-1163

  Zeimet, Alain G ^a   Riha, Karin ^a   Berger, Jennifer ^a   Widschwendter, Martin ^a   Hermann, Martin ^a   Daxenbichler, Günter ^a   Marth, Christian ^a  

^a UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

Author keywords

Adenovirus receptor; Chemosensitivity; Gene therapy; Ovarian cancer; p53

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYTOTOXIC AGENT; DNA; MULTIDRUG RESISTANCE PROTEIN; PROTEIN BCL 2; PROTEIN P53;

ADENOVIRUS; APOPTOSIS; CELL CYCLE; CHEMOSENSITIVITY; DNA DAMAGE; GENE THERAPY; GENETIC TRANSFECTION; HUMAN; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; RADIOSENSITIVITY; REVIEW; SIGNAL TRANSDUCTION; TUMOR CELL; TUMOR SUPPRESSOR GENE;

EID: 0034668186     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(00)00442-1     Document Type: Article

References (118)

1. Kress M., May E., Cassingena R., May P. Simian virus 40-transformed cells express new species of proteins precipitable by anti-simian virus 40 tumor serum. J Virol. 31:1979;472-483.
2. Lane D., Crawford L. T antigen is bound to a host protein in SV40-transformed cells. Nature. 278:1979;261-263.
3. Linzer D.I., Levine A.J. Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell. 17:1979;43-52.
4. Jenkins J.R., Rudge K., Currie G.A. Cellular immortalization by a cDNA clone encoding the transformation-associated phosphoprotein p53. Nature. 312:1984;651-654.
5. Eliyahu D., Raz A., Gruss P., Givol D., Oren M. Participation of p53 cellular tumour antigen in transformation of normal embryonic cells. Nature. 312:1984;646-649.
6. Oren M., Reich N.C., Levine A.J. Regulation of the cellular p53 tumor antigen in teratocarcinoma cells and their differentiated progeny. Mol Cell Biol. 2:1982;443-449.
7. May P., May E. Twenty years of p53 research Structural and functional aspects of the p53 protein . Oncogene. 18:1999;7621-7636.
8. Lane D.P. p53, guardian of the genome. Nature. 358:1992;15-16.
9. Clayman G.L., el-Nagger A.K., Roth J.A., Zhang W.W., Goepfert H., Taylor D.L., Liu T.J. In vivo molecular therapy with p53 adenovirus for microscopic residual head and neck squamous carcinoma. Cancer Res. 54:1995;1-6.
10. Zhang W.W., Fang X., Mazur W., French B.A., Georges R.N., Roth J.A. High efficiency gene transfer and high level expression of wild-type p53 in human lung cancer cells mediated by recombinant adenovirus. Cancer Gene Ther. 1:1994;5-13.
11. Yang C., Cirielli C., Capogrossi M.C., Passaniti A. Adenovirus-mediated wild-type p53 expression induces apoptosis and suppresses tumorigenesis of prostatic tumor cells. Cancer Res. 55:1995;4210-4213.
12. Hamada K., Zhang W.W., Alemany R., Wolf J., Roth J.A., Follen-Mitchell M. Growth inhibition of human cervical cancer cells with the recombinant adenovirus p53 in vitro. Gynecol Oncol. 60:1996;373-379.
13. Kim J., Hwang E.S., Kim J.S., You E.H., Lee S.H., Lee J.H. Intraperitoneal gene therapy with adenoviral-mediated p53 tumor suppressor gene for ovarian cancer model in nude mouse. Cancer Gene Ther. 6:1999;172-178.
14. Sewell D.A., Li D., Duan L., Schwartz M.R., O'Malley B.W. Jr. Optimizing suicide gene therapy for head and neck cancer. Laryngoscope. 107:1997;1490-1495.
15. Bergelson J.M., Cunningham J.A., Droguett G., Kurt-Jones E.A., Krithivas A., Hong J.S., Horwitz M.S., Crowell R.L., Firnberg R.W. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science. 275:1997;1320-1323.
16. Waes C.V. Cell adhesion and regulatory molecules involved in tumor formation, hemostasis and wound healing. Head Neck. 17:1995;140-147.
17. Kraiss S., Quaiser A., Oren M., Montenarh M. Oligomerization of oncoprotein p53. J Virol. 62:1988;4737-4744.
18. Pietenpol J.A., Tokino T., Thiagalingam S., el-Deiry W.S., Kinzler K.W., Vogelstein B. Sequence-specific transcriptional activation is essential for growth suppression by p53. Proc Natl Acad Sci USA. 91:1994;1998-2002.
19. el-Deiry W.S., Kern S.E., Pietenpol J.A., Kinzler K.W., Vogelstein B. Definition of a consensus binding site for p53. Nat Genet. 1:1992;45-49.
20. Yu J., Zhang L., Hwang P.M., Rago C., Kinzler K.W., Vogelstein B. Identification and classification of p53-regulated genes. Proc Natl Acad Sci USA. 96:1999;14517-14522.
21. Matlashewski G. p53 Twenty years on, Meeting Review . Oncogene. 18:1999;7618-7620.
22. Fields S., Jang S.K. Presence of a potent transcription activating sequence in the p53 protein. Science. 249:1990;1046-1049.
23. Clore G.M., Omichinski J.G., Sakaguchi K., Zambrano N., Sakamoto H., Appella E., Gronenborn A.M. High-resolution structure of the oligomerization domain of p53 by multidimensional NMR. Science. 267:1995;1515-1516.
24. Wang X.W., Vermeulen W., Coursen J.D., Gibson M., Lupold S.E., Forrester K., Xu G., Elmore L., Yeh H., Hoeijmakers J.H., Harris C.C. The XPB and XPD DANN helicases are components of the p53-mediated apoptosis pathway. Genes Dev. 10:1996;1219-1232.
25. Werness B., Levine A., Howley P. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science. 248:1990;76-79.
26. Yew P.R., Berk A.J. Inhibition of p53 transactivation required for transformation by adenovirus early 1B protein. Nature. 357:1992;82-85.
27. Momand J., Zambetti G.P., Olson D.C., George D., Levine A.J. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell. 69:1992;1237-1245.
28. Haupt Y., Maya R., Kazaz A., Oren M. Mdm2 promotes the rapid degradation of p53. Nature. 387:1997;296-299.
29. Wu X., Bayle J.H., Olson D., Levine A.J. The p53-mdm-2 autoregulatory feedback loop. Genes Dev. 7:1993;1126-1132.
30. Liang H and Lunec J, Characterisation of a novel p53 down-regulated promoter in intron 3 of the human MDM2 oncogene. In: Proceedings of 90th. Annual Meeting of the American Association for Cancer Research, Philadelphia, USA, 10-14 April 1999,40: p. 701. AACR Journal Service, Philadelphia, 1999.
31. Hainaut P., Milner J. A structural role for metal ions in the "wild-type" conformation of the tumor suppressor protein p53. Cancer Res. 53:1993;1739-1742.
32. Hainaut P., Milner J. Redox modulation of p53 conformation and sequence-specific DNA binding in vitro. Cancer Res. 53:1993;4469-4473.
33. Kaelin W.G. Jr. Another p53 Doppelganger? Science. 281:1998;57-58.
34. Abarzua P., LoSardo J.E., Gubler M.L., Spathis R., Lu Y.A., Felix A., Neri A. Restoration of the transcription activation function to mutant p53 in human cancer cells. Oncogene. 13:1996;2477-2482.
35. Kim A.L., Raffo A.J., Brandt-Rauf P.W., Pincus M.R., Monaco R., Abarzua P., Fine R.L. Conformational and molecular basis for induction of apoptosis by a p53 C-terminal peptide in human cancer cells. J Biol Chem. 274:1999;34924-34931.
36. Wang X.W., Forrester K., Yeh H., Feitelson M.A., Gu J.R., Harris C.C. Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3. Proc Natl Acad Sci USA. 91:1994;2230-2234.
37. Horikoshi N., Usheva A., Chen J., Levine A.J., Weinmann R., Shenk T. Two domains of p53 interact with the TATA-binding protein, and the adenovirus 13S E1A protein disrupts the association, relieving p53-mediated transcriptional repression. Mol Cell Biol. 15:1995;227-234.
38. Levine A.J. p53, the cellular gatekeeper for growth and division. Cell. 88:1997;323-331.
39. Cowell I.G., Okorokov A.L., Cutts S.A., Padget K., Bell M., Milner J., Austin C.A. Human topoisomerase II alpha and II beta interact with the C-terminal region of p53. Exp Cell Res. 255:2000;86-94.
40. Fu L., Ma W.L., Benchimol S. A translation repressor element resides in the 3′ untranslated region of human p53 mRNA. Oncogene. 18:1999;6419-6424.
41. Mosner J., Mummenbrauer T., Bauer C., Sczakiel G., Grosse F., Deppert W. Negative feedback regulation of wild-type p53 synthesis. EMBO J. 14:1995;4442-4449.
42. Shieh S.Y., Ikeda M., Taya Y., Prives C. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell. 91:1997;325-334.
43. Ashcroft M., Vousden K.H. Regulation of p53 stability. Oncogene. 18:1999;7637-7643.
44. Kirch H.C., Falswinkel S., Rumpf H., Brockmann D., Esche H. Expression of human p53 requires synergistic activation of transcription from the p53 promoter by AP-1, NF-κB and Myc/Max. Oncogene. 18:1999;2728-2738.
45. el-Deiry W.S., Tokino T., Velculescu V.E., Levy D.B., Parsons R., Trent J.M., Lin D., Mercer W.E., Kinzer K.W., Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell. 75:1993;817-825.
46. Deng C.X., Zhang P.M., Harper J.W., Elledge S.J., Leder P. Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell. 82:1995;675-684.
47. Waldman T., Kinzler K.W., Vogelstein B. p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res. 55:1995;5187-5190.
48. Sherr C.J. Tumor surveillance via the ARF-p53 pathway. Genes Dev. 12:1998;2984-2991.
49. Slebos R.J., Resnick M.A., Taylor J.A. Inactivation of the p53 tumor suppressor gene via a novel Alu rearrangement. Cancer Res. 58:1998;5333-5336.
50. Degregori J., Kowalik T., Nevins J.R. Cellular targets for activation by the E2F1 transcription factor include DNA synthesis- and G1/S-regulatory genes. Mol Cell Biol. 15:1995;4215-4224.
51. Degregori J., Leone G., Ohtani K., Miron A., Nevins J.R. E2F-1 accumulation bypasses a G1 arrest resulting from the inhibition of G1 cyclin-dependent kinase activity. Genes Dev. 9:1995;2873-2887.
52. Haupt Y., Rowan S., Oren M. p53-mediated apoptosis in HeLa cells can be overcome by excess pRB. Oncogene. 10:1995;1563-1571.
53. Rao L., White E. Bcl-2 and the ICE family of apoptotic regulators Making a connection . Curr Opin Genet Dev. 7:1997;52-58.
54. McCurrach M.E., Connor T.M., Knudson C.M., Korsmeyer S.J., Lowe S.W. Bax-deficiency promotes drug resistance and oncogenic transformation by attenuating p53-dependent apoptosis. Proc Natl Acad Sci USA. 94:1997;2345-2349.
55. Shikama N., Lee C.W., France S., Delavaine L., Lyon J., Krstic-Demonacos M., La Thangue N.B. A novel cofactor for p300 that regulates the p53 response. Mol Cell. 4:1999;365-376.
56. Sherr C.J., Weber J.D. The ARF/p53 pathway. Curr Opin Genet Dev. 10:2000;94-99.
57. Loughran O., La Thangue N.B. Apoptotic and growth-promoting activity of E2F modulated by MDM2. Mol Cell Biol. 20:2000;2186-2197.
58. Hiebert S.W., Packham G., Strom D.K., Haffner R., Oren M., Zambetti G., Cleveland J.C. E2F-1 DP-1 induces p53 and overrides survival factors to trigger apoptosis . Mol Cell Biol. 15:1995;6864-6874.
59. Buckbinder L., Talbott R., Velasco-Miguel S., Takenaka I., Faha B., Seizinger B.R., Kley N. Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature. 377:1995;646-649.
60. Eischen C.M., Leibson P.J. The Fas pathway in apoptosis. Adv Pharmacol. 41:1997;107-132.
61. Wu G.S., Burns T.F., McDonald E.R. 3rd, Meng R.D., Kao G., Muschel R., Yen T., el-Deiry W.S. Induction of the TRAIL receptor KILLER/DR5 in p53-dependent apoptosis but not growth arrest. Oncogene. 18:1999;6411-6418.
62. Bennett M., Macdonald K., Chan S.W., Luzio P.J., Simari R., Weissberg P. Cell surface trafficking of Fas A rapid mechanism of p53-mediated apoptosis . Science. 282:1998;290-293.
63. Wu G.S., Burns T.F., McDonald E.R. 3rd, Jiang W., Meng R., Krantz I.D., Kao G., Gan D.D., Zhou J.Y., Muschel R., Hamilton S.R., Spinner N.B., Markowitz S., Wu G., el-Deiry W.S. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat Genet. 17:1997;141-143.
64. Sheridan J.P., Marsters S.A., Pitti R.M., Gurney A., Skubatch M., Baldwin D., Ramakrishnan L., Gray C.L., Baker K., Wood W.I., Goddard A.D., Godowski P., Ashkenazi A. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science. 277:1997;818-821.
65. Polyak K., Xia Y., Zweier J.L., Kinzler K.W., Vogelstein B. A model for p53-induced apoptosis. Nature. 389:1997;300-305.
66. Meplan C., Richard M.J., Hainaut P. Redox signalling and transition metals in the control of the p53 pathway. Biochem Pharmacol. 59:2000;25-33.
67. Weinstein J.N., Myers T.G., O'Connor P.M., Friend S.H., Fornace A.J. Jr, Kohn K.W., Fojo T., Bates S.E., Rubinstein L.V., Anderson N.L., Buolamwini J.K., van Osdol W.W., Monks A.P., Scudiero D.A., Sausville E.A., Zaharevitz D.W., Bunow B., Viswanadhan V.N., Johnson G.S., Wittes R.E., Paull K.D. An information-intensive approach to the molecular pharmacology of cancer. Science. 275:1997;343-349.
68. Lowe S.W., Ruley H.E., Jacks T., Housman D.E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 74:1993;957-967.
69. Lowe S.W., Bodis S., McClatchey A., Remington L., Ruley H.E., Fisher D.E., Housman D.E., Jacks T. p53 status and the efficacy of cancer therapy in vivo. Science. 266:1994;807-810.
70. Pai H.H., Rochon L., Clark B., Black M., Shenouda G. Overexpression of p53 protein does not predict local-regional control or survival in patients with early-stage squamous cell carcinoma of the glottic larynx treated with radiotherapy. Int J Radiat Oncol Biol Phys. 41:1998;37-42.
71. Wiggenraad R., Tamminga R., Blok P., Rouse R., Hermans J. The prognostic significance of p53 expression for survival and local control in rectal carcinoma treated with surgery and postoperative radiotherapy. Int J Radiat Oncol Biol Phys. 41:1998;29-35.
72. Cote R.J., Esrig D., Groshen S., Jones P.A., Skinner D.G. p53 and treatment of bladder cancer. Nature. 385:1997;123-125.
73. Tada M., Matsumoto R., Iggo R.D., Onimaru R., Shirato H., Sawamura Y., Shinohe Y. Selective sensitivity to radiation of cerebral glioblastomas harboring p53 mutations. Cancer Res. 58:1998;1793-1797.
74. Brown J.M., Wouters B.G. Apoptosis, p53, and tumor cell sensitivity to anticancer agents. Cancer Res. 59:1999;1391-1399.
75. Zamble D.B., Jacks T., Lippard S.J. p53-dependent and -independent responses to cisplatin in mouse testicular teratocarcinoma cells. Proc Natl Acad Sci USA. 95:1998;6163-6168.
76. Pestell K.E., Hobbs S.M., Titley J.C., Kelland J.R., Walton M.I. Effect of p53 status on sensitivity to platinum complexes in a human ovarian cancer cell line. Mol Pharmacol. 57:2000;503-511.
77. waf1 in tumour response to radiation therapy. Oncogene. 18:1999;6540-6545.
78. Wang Q., Beck W.T. Transcriptional suppression of multidrug resistance-associated protein (MRP) gene expression by wild-type p53. Cancer Res. 58:1998;5762-5769.
79. Bartek J., Bartkova J., Vojtesek B., Staskova Z., Lukas J., Rejthar A., Kovarik J., Midgley C.A., Gannon J.V., Lane D.P. Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene. 6:1991;1699-1703.
80. Chen P.L., Chen Y., Bookstein R., Lee W.H. Genetic mechanisms of tumor suppression by the human p53 gene. Science. 250:1990;1576-1580.
81. Yonish-Rouach E., Resnitzky D., Lotem J., Sachs L., Kimchi A., Oren M. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature. 352:1991;345-347.
82. Frebourg T., Sadelain M., Ng Y.-S., Kassel J., Friend S.H. Equal transcription of wild-type and mutant p53 using bicistronic vectors results in the wild-type phenotype. Cancer Res. 54:1994;878-881.
83. Harvey M., Vogel H., Morris D., Bradley A., Bernstein A., Donehower L.A. A mutant p53 transgene accelerates tumour development in heterozygous but not nullizygous p53-deficient mice. Nat Genet. 9:1995;305-311.
84. Gannon J.V., Greaves R., Iggo R., Lane D.P. Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J. 9:1990;1595-1602.
85. Yewdell J.W., Gannon J.V., Lane D.P. Monoclonal antibody analysis of p53 expression in normal and transformed cells. J Virol. 59:1986;444-452.
86. Roth J.A. Targeting cancer genes A novel approach to cancer prevention and therapy . Cancer Bull. 45:1993;171-177.
87. Bosari S., Viale G., Radaelli U., Bossi P., Bonoldi E., Coggi G. p53 accumulation in ovarian carcinomas and its prognostic implications. Human Pathol. 24:1993;1175-1179.
88. Mujoo K., Maneval D.C., Anderson S.C., Gutterman J.U. Adenoviral-mediated p53 tumor suppressor gene therapy of human ovarian carcinoma. Oncogene. 18:1996;1617-1623.
89. Wills K.N., Maneval D.C., Menzel P., Harris M.P., Sutjipto S., Vaillancourt M.-T., Huang W.-M., Johnson D.E., Anderson S.C., Wen S.F., Bookstein R., Shepard H.M., Gregory R.J. Development and characterization of recombinant adenoviruses encoding human p53 for gene therapy of cancer. Hum Gene Ther. 5:1994;1079-1088.
90. Nielsen L.L., Dell J., Maxwell E., Armstrong L., Maneval D., Catino J.J. Efficacy of p53 adenovirus-mediated gene therapy against human breast cancer xenografts. Cancer Gene Ther. 4:1997;129-138.
91. Kieser A., Weich H.A., Brandner G., Marme D., Kolch W. Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression. Oncogene. 9:1994;963-969.
92. Waku T, Fujiwara T, Nishizaki M, Hizuta A, Nishimori H, Tokino T, Nakamura Y, Roth JA and Tanaka N, A proposed mechanism for the bystander effect of the p53 gene therapy: p53-Mediated antiangiogenic effect. In: Proceedings of 90th. Annual Meeting of the American Association for Cancer Research, Philadelphia, USA, 10-14 April 1999, 40: p. 730. AACR Journal Service, Philadelphia, 1999.
93. Wolf J.K., Mills G.B., Bazzet L., Bast R.C. Jr, Roth J.A., Gershenson D.M. Adenovirus-mediated p53 growth inhibition of ovarian cancer cells is independent of endogenous p53 status. Gynecol Oncol. 75:1999;261-266.
94. Gurnani M., Lipari P., Dell J., Shi B., Nielsen L.L. Adenovirus-mediated p53 gene therapy has greater efficacy when combined with chemotherapy against human head and neck, ovarian, prostate, and breast cancer. Cancer Chemother Pharmacol. 44:1999;143-151.
95. Nielsen L.L., Lipari P., Dell J., Gurnani M., Hajian G. Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate and breast cancer. Clin Cancer Res. 4:1998;835-846.
96. Zhang W., Kornblau S.M., Kobayashi T., Gambel A., McClain C.D., Claxton D., Diesseroth A.B. High levels of constitutive WAF1/Cip1 protein are associated with chemoresistance in acute myelogenous leukemia. Clin Cancer Res. 1:1995;1051-1057.
97. WAF1/Cip1 in human brain tumors. Oncogene. 11:1995;2021-2028.
98. WAF1 expression are reciprocally altered as ME-180 cervical carcinoma cells progress from high to low cisplatin sensitivity. Clin Cancer Res. 6:2000;193-202.
99. WAF1/CIP1 inhibits initiator caspase cleavage by TRAIL death receptor DR4. Biochem Biophys Res Commun. 269:2000;179-190.
100. WAF1 is required for cell cycle inhibition and suppression of apoptosis. J Interferon Cytokine Res. 19:1999;1351-1361.
101. Sato S., Kigawa J., Minagawa Y., Okada M., Shimada M., Takahashi M., Kamazawa S., Terakawa N. Chemosensitivity and p53-dependent apoptosis in epithelial ovarian carcinoma. Cancer. 86:1999;1307-1313.
102. Gershenson D.M., Deavers M., Diaz S., Tortolero-Luna G., Miller B.E., Bast R.C. Jr, Mills G.B., Silva E.G. Prognostic significance of p53 expression in advanced-stage ovarian serous borderline tumors. Clin Cancer Res. 5:1999;4053-4058.
103. Abendstein B., Marth C., Mueller-Holzner E., Widschwendter M., Daxenbichler G., Zeimet A.G. Clinical significance of serum and ascitic p53 autoantibodies in epithelial ovarian carcinoma. Cancer. 88:2000;1432-1437.
104. Zeimet AG, Abendstein B, Widschwendter M, Müller-Holzner E and Marth C, Prognostic impact of the humoral immune response against p53 protein in advanced epithelial ovarian cancer. In: 7th Biennial Meeting of the International Gynecologic Cancer Society, Rome, Italy, 26-30 Sept. 1999 (Eds. Pecorelli S, Atlante G, Benedetti Panici P and Mancuso S), pp. 341-345. Monduzzi Editore, Bologna, 1999.
105. Runnebaum I.B. Intraperitoneale p53-Gentherapie des Ovarialkarzinoms in der klinischen Prüfung Interimsanalyse eines vielversprechenden Ansatzes zur "kausalen" Therapie . Arch Gynecol Obstet. 263:(Suppl 2):1999;166-168.
106. Stevenson S.C., Rollence M., White B., Weaver L., McClelland A. Human adenovirus serotypes 3 and 5 bind to two different cellular receptors via the fiber head domain. J Virol. 69:1995;2850-2857.
107. 5 promote adenovirus internalization but not virus attachment. Cell. 73:1993;309-319.
108. Dechecchi M.C., Tamanini A., Bonizzato A., Cabrini G. Heparan sulfate glycosaminoglycans are involved in adenovirus type 5 and 2-host cell interactions. Virology. 268:2000;382-390.
109. Yingming L., Pong R.-C., Bergelson J.M., Hall M.C., Sagalowski A.I., Tseng C.-P., Wang Z., Hsieh J.-T. Loss of adenoviral receptor expression in human bladder cancer cells A potential impact on the efficacy of gene therapy . Cancer Res. 59:1999;325-330.
110. Grace M.J., Xie L., Musco M.L., Cui S., Gurnani M., DiGiacomo R., Chang A., Indelicato S., Syed J., Johnson R., Nielsen L.L. The use of laser scanning cyometry to assess depth of penetration of adenovirus p53 gene therapy in human xenograft biopsies. Am J Pathol. 155:1999;1869-1878.
111. Kasono K., Blackwell J.L., Douglas J.T., Dmitriev I., Strong T.V., Reynolds P., Kropf D.A., Carroll W.R., Peters G.E., Bucy R.P., Curiel D.T., Krasnykh V. Selective gene delivery to head and neck cancer cells via an integrin targeted adenoviral vector. Clin Cancer Res. 5:1999;2571-2579.
112. Miller R.M., Buchsbaum D.J., Reynolds P.N., Douglas J.T., Gillespie G.Y., Mayo M.S., Raben D., Curiel D.T. Differential susceptibility of primary and established human glioma cells to adenovirus infection Targeting via the epidermal growth factor receptor achieves fiber receptor-independent gene transfer . Cancer Res. 58:1998;5738-5748.
113. Goldman C.K., Rogers B.E., Douglas J.T., Sosnowski B.A., Ying W., Siegal J.P., Baird A., Campain J.A., Curiel D.T. Targeted gene delivery to Kaposi's sarcoma cells via the fibroblast growth factor receptor. Cancer Res. 57:1997;1447-1451.
114. Bischoff J.R., Kirn D.H., Williams A., Heise C., Horn S., Muna M., Ng L., Nye J.A., Sampson-Johannes A., Fattaey A., McCormick F. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science. 274:1996;373-376.
115. Vasey P.A., Seiden M., O'Neill V., Campo S., Johnston S., Davis J., Kirn D., Kaye S.B., Shulman L.N. Phase I trial of intraperitoneal onyx-015 adenovirus in patients with recurrent ovarian cancer. J Clin Oncol. 19:2000;382a.
116. Foster B.A., Coffey H.A., Morin M.J., Rastinejad F. Pharmacological rescue of mutant p53 conformation and function. Science. 286:1999;2507-2510.
117. Shatrov V.A., Ameyar M., Bouquet C., Cai Z., Stancou R., Haddada H., Chouaib S. Adenovirus-mediated wild-type-p53-gene expression sensitizes TNF-resistant tumor cells to TNF-induced cytotoxicity by altering the cellular redox state. Int J Cancer. 85:2000;93-97.
118. Roh H., Pippin J., Drebin J.A. Down-regulation of HER2/neu expression induces apoptosis in human cancer cells that overexpress HER2/neu. Cancer Res. 60:2000;560-565.